Postpartum haemorrhage
Conditions
Interventions
Group 1
Group 2
Group 3
Sponsors
Rasheedat Balogun
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Healthy pregnant women at term
Exclusion criteria
Exclusion criteria: Women with history of, or being treated for bleeding disorder Women with intrauterine fetal demise Women with antepartum haemorrhage Women requiring general anaesthesia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| -Uterine contractility by palpation (as recommended by WHO)13, at two and five minutes by the attending accoucheur after intravenous administration of the study drug. This is because of the onset of action of carbetocin at 2 minutes with contractions lasting for about 6 minutes following its administration2. - Estimated blood loss after intravenous administration of the study drug. | — |
Secondary
| Measure | Time frame |
|---|---|
| -The use of additional uterotonic agents, -The need for blood transfusion. -The need for additional surgical interventions such as hysterectomy -The occurrence of side effects (hypo/hypertension, brady/tachycardia, nausea/vomiting, flushing, headache, others) following the administration of the study drug. | — |
Countries
Nigeria
Contacts
Public ContactRasheedat Balogun
Senior Registrar OBGYN
Outcome results
None listed